|
Patent landscape, scope, and claims: |
Executive summary
US Patent 5,739,135 is a large-coverage composition-of-matter patent centered on a broad structural class of MTP inhibitor small molecules with a fluorenyl-type or indenyl-type aromatic core, a piperidine (incl. N-oxide) motif, and a flexible substitution pattern. The independent compound claim (Claim 1) is drafted as a high-variance Markush formula: it ranges over multiple linkage types, heteroatom placements (bond/O/S/N), linker lengths, and broad aryl/heteroaryl substitution definitions. The patent also includes method-of-treatment claims for atherosclerosis, pancreatitis secondary to hypertriglyceridemia, hyperglycemia, obesity, and lipid lowering by MTP inhibition.
From the claims provided, the estate’s practical scope is anchored on the presence of: (i) the specific “Q” substituent class, (ii) a fluorenyl/indenyl-type group as “R1”, (iii) the piperidine linkage region with allowances for N-oxide, salts, and geometric variants, and (iv) the MTP-inhibitory pharmacological framing in the method claims (Claims 15-16, 31-32, 35-38).
US Patent 5,739,135 scope and claims: what is protected?
US 5,739,135 protects (1) a broad family of specific chemical structures defined by Markush-style variables and (2) therapeutic methods where the administered compound is from that chemical family and the therapeutic effect is tied to MTP inhibition.
What is the independent composition claim coverage (Claim 1)?
Claim 1 defines “a compound” having a specified core structure where key variables are:
- Q: a defined linker/substituent fragment (given in the claim as an image placeholder).
- R1: either a fluorenyl-type group (Claim 1 text explicitly: “R1 is a fluorenyl-type group”).
- Z1 and Z2: independently a bond, O, S, or (a further heteroatom/bond option), with the proviso that “with respect to B, at least one of Z1 and Z2 will be other than a bond.”
- R11: a bond or short alkylene/alkenylene/alkynylene (≤10 carbons) or arylene / mixed arylene-alkylene.
- R12: broad substitution at a key position including H/alkyl/alkenyl/aryl and multiple haloalkyl options; restricted by two provisos:
- If R12 = H and R12 is present in specific cases of aryloxy/alkoxy/arylalkoxy, then Z2 must be a particular ring fragment or a bond.
- If Z2 is a bond, R12 cannot be heteroaryl or heteroarylalkyl.
- Z: bond, O, S, N-alkyl, N-aryl, or short alkylene/alkenylene (1–5 carbons).
- R13-R16: independently selected from a wide set (H, alkyl, halo, aryl, cycloalkyl, heteroaryl, hydroxy, alkoxy, nitro, amino, sulfonyl/thio variants, carbonyl-containing groups, etc.).
- R5: the most expansive aryl/heteroaryl substitution definition, allowing many substituents (halo, alkoxy, nitro, cyano, amino, thiol, thioethers, sulfonyl/sulfinyl, carbonylamino, etc.), optionally substituted with 1–4 groups.
- R6: H, C1–C4 alkyl, or C1–C4 alkenyl, with optional substitution (1–4 groups) using the same wide list as R5.
- “B” and the remaining ring system choices: the claim includes heteroaryl-containing 5- or 6-member members for some variables and explicitly covers N-oxides.
- Salts: pharmaceutically acceptable salts.
Claim 1 therefore is a broad genus with numerous carve-like logical constraints (the Z2/B/R12 linking restrictions) plus extensive tolerance of aromatic, heteroaromatic, and functional group diversity.
Which specific structural elements are repeatedly emphasized across dependent claims?
Even where the claim text is partially image-replaced, multiple dependent claims anchor the genus to practical, manufacturable embodiments:
- Fluorenyl-based and/or indenyl-based core (R1).
- A piperidine unit in the substituted linker region.
- Permitted N-oxides of the compounds.
- Extensive aryl substitution at R5, including trifluoromethylalkyl/alkyl and ortho-substituted aryl patterns (seen in Claims 7, 11).
- Allowance for different linkers (R11) and heteroatoms in link positions (Z1/Z2, Z as bond/O/S/N-alkyl/N-aryl).
Which dependent claims narrow Claim 1 to particular embodiments?
How do Claims 2-4 define narrower formulas?
- Claim 2 and Claim 3 add additional formula limitations (given as image placeholders).
- Claim 4 narrows R1 to a specific fluorenyl-type embodiment (“R1 is a fluorenyl-type group of the structure …”).
These claims are typical of Markush families: they reduce dimensionality by fixing one or more variable fragments while keeping the rest of the genus open.
What is the practical narrowing in Claim 5?
Claim 5 sets multiple specific constraints:
- R1 is a particular fluorenyl-type group.
- Z is a bond, O, or S.
- R13-R16 are each H, with a pattern where one pair is halogen (explicitly “one of R15 and R16 and one of R13 and R14 are halogen”).
- Z1 is bond or C═O.
- R11 is alkylene or alkenylene.
- R12–Z2 is a specific fragment, and R12a is restricted to alkyl, fluorinated lower alkyl, or polyfluorinated lower alkyl.
Claim 5 therefore is a chemically meaningful subgenus: it locks down substitution sparsity (mostly H plus limited halogens) and enforces fluorinated lower alkyl content at the R12 position.
How do Claims 6-11 narrow to “simpler” substituent sets?
- Claim 6: fixes R1 to a specific fluorenyl-type, and restricts R11 (alkylene/alkenylene), R12 to H/alkyl/alkenyl/aralkyl/aralkenyl, and R13 and R15 to H or F; Z to O/S/bond.
- Claim 7 and Claim 11: describe a larger narrowed substructure with:
- R5 chosen from cycloalkyl/phenyl/aryl/heteroaryl, but with specific ortho substitution rules (alkyl/alkoxy/haloalkyl with up to 5 halogens, trifluoromethyl, aryloxy/haloalkoxy with up to 5 halogens, arylalkyl/arylalkoxy).
- R6 H or CH3
- R13 and R15 H or F
- Z1 bond
- R11 alkylene
- R12–Z2 fixed to a specific fragment, or Z2 bond with R12 alkyl.
- Claim 8: additionally narrows R11 to --(CH2)4 -- and locks Z1 = bond and R12–Z2 to a specific fragment.
- Claims 9-10: restrict the structure further with explicit R12 = trifluoromethylalkyl/alkyl or other fixed forms.
These claims suggest the patent’s internal “cascade”: genus → fluorenyl/indenyl subset → substitution pattern subset → specific linker and fluorinated side-chain subset.
How do the “listed examples” in Claim 12 expand into a protected set?
Claim 12 enumerates many specific compounds by systematic names using the same core motif:
- They include fluorene-9-carboxamide and variants with different:
- piperidine linker length (butyl, pentyl, ethyl, propyl style naming),
- piperidine substitution position (2,7-difluoro vs 3,6-difluoro vs unsubstituted),
- amide N-substituent choices (propyl, 2,2,2-trifluoroethyl; benzoyl, phenoxybenzoyl, phenylsulfonyl, acetylamino, tert-butyl carbonate protected (1,1-dimethylethoxy)carbonyl style, sulfonyl),
- core aromatic system either fluorene or thioxanthene (Claim 12 includes both “9H-fluorene” and “9H-thioxanthene” entries),
- and N-oxide and salt coverage is explicitly tied to these named structures via “and a pharmaceutically acceptable salt… and an N-oxide…”.
From an infringement-analysis standpoint, this enumeration matters because:
- it reveals the patent drafter’s view of key market-relevant embodiments,
- it can be used to interpret the broad Markush terms (the enumerated structures tend to anchor claim construction).
What method-of-use rights are included, and what triggers them?
What do the method claims require (MTP inhibition framing)?
The method claims in the provided text explicitly tie therapeutic use to the mechanism:
- Claim 15: preventing/treating atherosclerosis, pancreatitis secondary to hypertriglyceridemia, hyperglycemia (including pathways via MTP inhibition by reduced dietary fat absorption, lowered triglycerides through MTP inhibition, and/or decreased absorption of free fatty acids), and obesity via reduced malabsorption of dietary fat, by administering a therapeutically effective amount of a compound defined in Claim 1.
- Claim 16: method of lowering serum lipid levels and multiple dyslipidemia conditions, by administering a Claim 1 compound.
Similar method-of-use claims reappear:
- Claims 31-32 tied to compounds defined in Claim 28.
- Claims 35-38 tied to compounds having specific fluorenyl/indenyl structures, again framed around MTP inhibition and lipid/hyperglycemia/obesity/atherosclerosis treatment.
Where is the boundary between compound protection and use protection?
- The patent’s strong chemical coverage is in the compound claims (e.g., Claim 1 and follow-ons).
- The method claims are secondary rights that are triggered only when an accused product is the claimed compound family and is used to treat the specified conditions via the MTP inhibition therapeutic effect language.
How does Claim 20 and Claim 21 show stereochemical and oxide breadth?
What do the “cis-” embodiments (Claim 20) add?
Claim 20 explicitly lists cis- configurations for at least two named N-oxide compounds:
- cis-9-... piperidinyl-butyl-N-propyl-9H-fluorene-9-carboxamide, N-oxide
- cis-9-... (2-phenoxybenzoyl)amino... N-(2,2,2-trifluoroethyl) ... , N-oxide
This indicates the specification and legal coverage encompass stereochemical isomers and the N-oxide derivative forms.
What does Claim 21 protect about R5 and R12-Z2?
Claim 21 defines:
- R5 as phenyl substituted with aryl where aryl is phenyl substituted with trifluoromethyl.
- R6 H; R13 and R15 H; and fixes R12–Z2 fragment behavior.
- It includes Z1 as bond or N-oxides.
This signals a narrower but commercially plausible subgenus: CF3-aryl patterns and fixed fluorinated side-chain topology.
Which claim sets cover N-oxides and salts explicitly?
Across the claims provided:
- Claim 1 includes “N-oxides thereof” and “pharmaceutically acceptable salts thereof.”
- Claim 12 explicitly includes N-oxides for the enumerated structures.
- Claim 20 includes N-oxide explicitly.
- Claim 24 includes “including the piperidine N-oxide thereof or a pharmaceutically acceptable salt thereof.”
As a result, an entry strategy that modifies only the N-oxide state is still within claim scope if the base compound skeleton matches.
Patent landscape implications: what does this estate likely block?
How broad is the “design space” protected?
Given the breadth of R5 and R13-R16 substituent definitions, US 5,739,135 likely blocks at least:
- Many fluorene- and thioxanthene-like aromatic MTP inhibitors with piperidine linkages.
- Variants differing in:
- amide N-substituent (benzoyl, phenoxybenzoyl, phenylsulfonyl, acetyl, carbonate-protected forms),
- piperidine N-oxide state,
- fluorine substitution pattern on the piperidine (2,7- and 3,6-difluoro appear in Claim 12),
- and choice of fluorinated lower alkyl (notably 2,2,2-trifluoroethyl appears repeatedly).
The Markush architecture makes this patent resilient against “single-point” changes, unless the change removes an essential structural relationship such as:
- the fluorenyl/indenyl R1 core type,
- the specific Q fragment connectivity,
- or the Z/Z1/Z2 linkage constraints that tie R12 behavior to the heteroatom/bond selection.
Where are likely “escape hatches” in claim logic?
The claim includes explicit conditional prohibitions:
- If Z2 is a bond, R12 cannot be heteroaryl or heteroarylalkyl.
- If R12 = H and Z2 must follow certain fragment allowances for aryloxy/alkoxy/arylalkoxy cases.
These conditional structures can reduce coverage for certain heteroaryl-linked substitution strategies.
Is this patent likely to cover generic entry via different salts, oxides, or minor analogs?
Salts
Because claims repeatedly cover “pharmaceutically acceptable salts,” generic attempts to avoid infringement by using a different salt form alone are unlikely to avoid coverage if the underlying compound matches.
N-oxides
Because N-oxides are explicitly included at multiple claim levels, avoiding infringement by switching N-oxide vs non-oxide state is unlikely if the alternative form is still within the explicitly defined “N-oxide thereof” or if the claimed compounds are interpreted to include oxide states.
Minor analogs
The broad R5 and R13-R16 enumerations permit many substituent changes while remaining within scope. Launch-risk analysis tends to focus on whether the competitor’s scaffold:
- remains within the defined fluorenyl/indenyl and Q/piperidine relationship,
- and respects the Z1/Z2 and R12 conditional restrictions.
Key takeaways
- US 5,739,135 is a broad Markush composition patent with a fluorenyl-type (and related indenyl-type) aromatic core, a piperidine motif, and extensive substitution tolerance across amide N-substituents and aryl/heteroaryl substitutions.
- Claim 1 provides the widest chemical genus; numerous dependent claims narrow by fixing specific linker lengths, heteroatom/bond placements, fluorinated side-chain forms, and substituent patterns.
- The patent includes method-of-use claims for atherosclerosis, hypertriglyceridemia-related pancreatitis, hyperglycemia, obesity, and broad lipid lowering, each framed through MTP inhibition and requiring administration of a compound defined in the corresponding compound claim.
- Explicit coverage of N-oxides and pharmaceutically acceptable salts reduces common generic “workarounds” unless the competitor changes the chemical scaffold beyond the conditional constraints in Z1/Z2 and R12 logic.
FAQs
-
Do the method claims cover any MTP inhibitor, or only compounds that match the specific structural definitions?
Only compounds defined in the referenced compound claims trigger the method-of-use claims, as written.
-
Can a competitor avoid infringement by switching the piperidine N-oxide state?
The claims explicitly include N-oxides and “piperidine N-oxide” coverage in multiple dependent claims, so oxide state changes alone do not automatically remove coverage.
-
Which substituent variables likely determine whether an analog falls inside or outside Claim 1?
The conditional linkage logic among Z1/Z2, R12, and the “Q” and R1 core relationships are the most consequential claim-logic constraints beyond pure substituent selection.
-
Are stereochemical variants such as “cis” included?
Yes. Claim 20 explicitly lists cis embodiments with N-oxide forms.
-
Does the enumerated list in Claim 12 expand legal scope beyond Claim 1’s Markush genus?
The listed compounds provide concrete embodiments within the broader Markush definitions and indicate the patent’s intended coverage, while the broader Markush claim language remains the primary scope driver.
References (APA)
- United States Patent No. 5,739,135. (n.d.). Compounds and methods for treatment via MTP inhibition (claims as provided). United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
